NCT05792007 Study of the Medullary Microenvironment in Acute Childhood Leukemia
| NCT ID | NCT05792007 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Tours |
| Condition | Acute Lymphoid Leukemia |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2023-10-26 |
| Primary Completion | 2026-10-25 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2023-10-26 with a primary completion date of 2026-10-25.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Acute leukemia (AL) is the most common cancer in children. Despite the optimization of chemotherapy treatments and the development of supportive care, a certain number of LAs relapse and/or progress to death of the child. It therefore seems essential to try to better understand the physiopathology and the mechanisms of resistance to treatment of these diseases.
Eligibility Criteria
Inclusion Criteria: * for patients with AL: 1. Child with acute lymphoblastic or myeloblastic leukemia at diagnosis 2. Not having received prior hematological treatment 3. Aged 1 to 15 years old 4. Whose 2 parents, or the holder of parental authority, have signed a consent enlightened. 5. Affiliated patient or beneficiary of a social security scheme. * Control group patients: 1. Child undergoing orthopedic surgery exposing the bone marrow (osteotomy of the pelvis). 2. Aged between 1 and 15 years old. 3. Having no pathology of hematological origin. 4. Not having received any treatment that could interfere with the functioning of the bone marrow. 5. Whose 2 parents or the holder of parental authority have signed a consent enlightened. 6. Affiliated patient or beneficiary of a social security scheme. Exclusion Criteria: * for patients with AL: 1. Patient under 1 year old and over 15 years old. 2. Contraindication to myelogram. 3. Absence of signature of the informed consent by the 2 parents or the holder of parental authority. 4. Patients with relapsed acute lymphoblastic or myeloblastic leukemia. 5. Having received prior hematological treatments. 6. Parents with physical or mental condition not allowing to understand the informed consent. * Control group patients 1. Patient under 1 year old and over 15 years old. 2. Having an underlying haematological pathology. 3. Absence of signature of the informed consent by the 2 parents or the holder of parental authority. 4. Having received prior hematological treatments. 5. Parents with physical or mental condition not allowing to understand informed consent.
Contact & Investigator
Olivier HERAULT, MD-PhD
STUDY DIRECTOR
University Hospital of TOURS
Frequently Asked Questions
Who can join the NCT05792007 clinical trial?
This trial is open to participants of all sexes, aged 1 Year or older, up to 15 Years, studying Acute Lymphoid Leukemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05792007 currently recruiting?
Yes, NCT05792007 is actively recruiting participants. Contact the research team at olivier.herault@univ-tours.fr for enrollment information.
Where is the NCT05792007 trial being conducted?
This trial is being conducted at Tours, France, Tours, France, Tours, France.
Who is sponsoring the NCT05792007 clinical trial?
NCT05792007 is sponsored by University Hospital, Tours. The principal investigator is Olivier HERAULT, MD-PhD at University Hospital of TOURS. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.